ModifiedUnitedHealthcarePolicy CS069.T

Light and Laser Therapy

Defines UnitedHealthcare coverage rationale, criteria, and coding guidance for light and laser therapies (e.g., pulsed dye laser, fractional ablative lasers, laser hair removal) for dermatologic conditions and affected patient populations (vascular lesions, hypertrophic burn scars, pilonidal disease, acne, onychomycosis, rosacea/rhinophyma).

Policy Summary

PayerUnitedHealthcare

PolicyLight and Laser Therapy

Policy CodePolicy CS069.T

Change TypeRevisions to examples of unproven therapiesCPT code removalcontent edits

Effective DateFebruary 1, 2026

Next Review DateN/A

Key ActionWhen requesting prior authorization, document prior standard therapies and provide medical records demonstrating clinical criteria (eg, scar scales, treatment history) as specified in the policy.

SourceLink

POLICY UPDATE CHANGES

Updated list of examples of unproven and not medically necessary light and laser therapies; removed 'excimer'.

Removed CPT code 96999 from Applicable Codes.

Removed language indicating excimer laser therapy is considered cosmetic and not medically necessary for treatment of vitiligo.

Medical Records Documentation Used for Reviews: Added language indicating medical records may be required to assess whether the member meets clinical criteria for coverage.

Removed content/language pertaining to the state of Louisiana.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

PDL supported for PWS/IHPDL coverage

Fractional ablative laser listedScar therapy

Laser hair removal indication

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Multiple citedSystematic reviews

Coverage Criteria and Indications

Medically Necessary Indications

Covered when ALL of the following are met for listed indications

Pulsed dye laser for vascular lesions: Pulsed dye laser therapy is considered proven and medically necessary for port-wine stains and cutaneous hemangioma/hemangiomata.

PDL with epidermal cooling commonly used; evidence summaries support safety and efficacy for PWS/IH.

Laser hair removal for pilonidal disease: Laser hair removal is proven and medically necessary for the treatment of pilonidal sinus disease that has been, or is being, treated with surgery for control of hair regrowth.

Pilonidal disease pathogenesis linked to hair; LHR used as adjunct to surgery.

Fractional ablative laser for hypertrophic burn scars: Fractional ablative laser fenestration (e.g., CO2, Er:YAG) of hypertrophic burn scars is proven and medically necessary when (1) the burn scar is causing functional impairment (i.e., limiting range of motion) and the treatment can be reasonably expected to improve the functional impairment; and (2) the individual has tried and failed at least one conventional treatment (e.g., hypoallergenic paper tape, pressure garments, or silicone kits with gel/sheeting).

Codes 0479T/0480T describe billing units for this therapy.

Unproven / Not Medically Necessary Indications

Not medically necessary / unproven for the following indications due to insufficient evidence

Unproven indications: Light and laser therapy (including IPL, phototherapy, PDT, Nd:YAG, PDL) is unproven and not medically necessary for acne vulgaris, onychomycosis, rhinophyma, and rosacea.

Evidence insufficient to support efficacy for these conditions.

Infantile Hemangiomas - coverage context

Coverage considerations summarized from evidence and guideline statements in the document segment

Infantile hemangiomas (IH): Laser therapy (most commonly PDL with epidermal cooling) is generally considered for residual cutaneous changes after completion of the proliferative growth phase or for medically refractory lesions after pharmacologic management (eg, propranolol); decision-making should involve a hemangioma specialist, especially in young infants.

Evidence: systematic reviews show heterogeneous studies with low to insufficient strength; lasers may be more effective than observation for lesion size but beta-blockers are primary therapy.

Pilonidal Disease - coverage context

Laser hair depilation (LHD/LE) considered as adjunct or primary adjunctive therapy to reduce recurrence after standard care or surgery for pilonidal disease

Pilonidal Sinus Disease (PSD): Randomized trials and systematic reviews report lower recurrence rates with laser epilation compared with conventional hair removal or standard care in several studies; guidelines (ASCRS, SICCR) state elimination of hair by shaving or laser epilation may be used as a primary or adjunctive treatment, but evidence is low and recommendations are weak.

Trial limitations include single-center designs, heterogeneity, and variable follow-up; device selection often based on Fitzpatrick skin type.

Hypertrophic Burn Scars - coverage context

Fractional and ablative CO2 laser treatments considered for symptomatic hypertrophic burn scars where conservative measures have failed

Hypertrophic Burn Scars: Ablative fractional CO2 and fractional CO2 lasers have been associated with reduced scar thickness, improved scar assessment scores and patient-reported outcomes; treatments are often delivered serially (eg, 1-4 sessions) with adjunctive topical or intralesional corticosteroid application.

Evidence from cohort studies shows mean 21% thickness reduction and low rates of infection/delayed healing; effectiveness varies by body region and burn etiology.

Evidence-supported indications for laser therapy in hypertrophic burn scars

Covered when ALL of the following are met (evidence summary):

Study-supported clinical criteria: Patients have symptomatic or functionally limiting hypertrophic burn scars (e.g., pruritus, contracture, thickness) documented with scar assessment scales (VSS/POSAS/mVSS); prior conservative therapies have been tried or documented; treatment plan specifies use of ablative fractional CO2 or other laser modality supported by literature; expected number and interval of treatments align with published series (commonly 1–4 sessions, often spaced 4–8 weeks)1-4 sessions; intervals commonly 4-8 weeks

Evidence includes multiple systematic reviews, meta-analyses, and cohort studies reporting improvements in validated scar scores and scar characteristics

Photodynamic therapy (PDT) — conditional coverage

Coverage stance derived from guideline recommendations and evidence summaries:

PDT for adults with moderate-to-severe acne: Covered when ALL of the following are met: (1) patient is age 18 or older; (2) moderate-to-severe acne; (3) documented failure, intolerance, or contraindication to standard therapies (topical combinations, oral antibiotics with topical agents, and isotretinoin when indicated); (4) treatment plan references PDT (ALA or MAL) with defined light source and treatment parameters; and (5) documentation of baseline and post-treatment IGA and lesion counts.see text

Based on NICE 'consider' recommendation and limited RCT evidence

Non-PDT light and laser therapies — limited/experimental

Coverage stance for other light and laser therapies:

Non-PDT light and laser therapies (e.g., blue light, red light, IPL, Nd:YAG, PDL): Not routinely covered/considered investigational or of uncertain benefit unless high-quality evidence is provided for the specific device and indication; these therapies lack consistent RCT evidence demonstrating superiority to standard acne treatments.N/A

AAD and Cochrane conclude evidence insufficient; studies heterogeneous and often low quality

Coverage summary for device-based dermatologic therapies (this section)

Summary coverage logic informed by guideline statements and systematic reviews in this section:

Photodynamic therapy for acne (NICE conditional): Consider PDT for adults (≥18) with moderate to severe acne only when other treatments are ineffective, not tolerated, or contraindicated — evidence limited; not a strong recommendation.age >= 18; prior standard therapy failure/intolerance

NICE 'consider' recommendation based on small studies; AAD states evidence insufficient for firm recommendations.

Laser/light therapies for acne: Available RCTs and reviews provide insufficient evidence to make definitive recommendations for most laser and light-based devices for acne (multiple wavelengths/modalities studied); consider only within investigational/clinical-trial settings or when documented prior therapies have failed.document prior pharmacologic therapy and rationale

AAD 2024: evidence insufficient; further RCTs needed.

Onychomycosis — combination laser + topical antifungal:

Device-based therapy — conditional coverage with clinical justification

Coverage/clinical stance summary based on evidence and specialty guidance

General coverage considerations: Laser and light-based therapies (PDL, LPAL, LPAN, IPL, KTP, Nd:YAG, Er:YAG, CO2) may be considered for management of persistent facial erythema and telangiectasia, and for select phymatous changes, when clinically appropriate and documented. Evidence is largely from small randomized or observational studies and consensus guidance; efficacy for severe telangiectasia is less certain.

Supported by randomized split-face trials and multiple small studies; specialty societies consider these therapies as options but note limited/high variability in evidence.

Factors supporting use: Supportive factors include: phenotype of erythema/telangiectasia (ETR), failure or intolerance of medical topical/systemic therapies, patient preference for device treatment, and for mild–moderate rhinophyma where ablative Er:YAG or CO2 have shown benefit in small series.

Studies cited: LPAL vs PDL non-inferiority (Park 2022), LPAN vs PDL (Seo 2016), Er:YAG for rhinophyma (Badawi 2020).

Limitations and non-ideal scenarios: Do not expect uniformly high-quality evidence; severe telangiectasia and granulomatous rosacea have less consistent device response and may be less likely to benefit (DPL not optimal for severe telangiectasia per Zhao 2020). Clinical judgment required and further RCT data needed.

Viral warts and plantar warts are not vascular proliferative lesions and therefore should not be billed or reported using the cutaneous vascular lesion destruction codes 17106, 17107, or 17108. When laser is used to treat warts, use an appropriate procedure code for wart destruction or an unlisted procedure code as applicable, but do not classify wart treatment as a vascular lesion procedure.

Systematic reviews and comparative studies encompass many laser types and heterogeneous protocols; available data do not demonstrate a clear superiority of any single laser modality for most indications. Variability in laser type, pulse width, cooling, endpoints, and study populations limits the ability to draw definitive comparative-effectiveness conclusions.

Multiple systematic reviews and guideline reviews conclude that the evidence base for laser and light therapies in acne is limited, short-term, and heterogeneous. Trials frequently have small sample sizes, use different wavelengths or PDT protocols, and lack long‑term follow-up; consequently evidence is insufficient to support routine recommendation of laser/light therapies as standard acne treatment.

Because high-quality, consistent evidence is lacking, light and laser therapies for acne are routinely excluded when proposed as first-line treatments without documentation of prior adequate trials of guideline-recommended topical and systemic therapies. Photodynamic therapy may be considered only under the narrow circumstances described by NICE (adults ≥18 with moderate–severe acne after failure/intolerance of standard therapies) and with appropriate documentation.

Routine coverage is not supported for most light- and laser-based treatments for acne, onychomycosis, rosacea, and rhinophyma because the available studies are small, heterogeneous, and of low to very low quality. Except for limited, evidence‑supported contexts (e.g., PDT for adult acne after failure of standard therapy, or adjunctive laser plus topical antifungal for onychomycosis in select studies), these modalities should be considered investigational or not medically necessary.

Device limitations are noted for certain presentations: for example, dye pulsed light (DPL) and similar devices have limited efficacy for severe telangiectasia in erythematotelangiectatic rosacea (ETR). Evidence for some rosacea presentations is based on small, nonrandomized studies, so DPL and related devices are not considered optimal for severe telangiectatic disease without supporting clinical justification.

Language and content specific to the state of Louisiana have been removed from this policy during the recent template update and revision to the Applicable Codes and supporting sections.

Summary: For acne vulgaris, onychomycosis, rhinophyma, and rosacea, light and laser therapies are considered unproven and not medically necessary in routine practice due to insufficient, heterogeneous, or low‑quality evidence. Established first‑line pharmacologic and topical therapies remain the preferred approach except in narrowly defined, documented circumstances.

Because studies vary widely in device type, protocols, and outcomes, the routine primary use of lasers in place of established first‑line therapies is not supported. Heterogeneity and methodological limitations mean lasers should usually be reserved for residual, refractory, or trial settings where prior standard therapies have failed or are not tolerated.

Conclusion for acne: available randomized trials and reviews do not provide high‑quality, consistent evidence that laser or light therapy is an effective primary treatment for acne vulgaris. The literature is characterized by short follow-up, small samples, variable devices/wavelengths, and risk of bias.

Operational exclusion: requests to authorize laser or other light‑based device procedures for acne that lack documentation of prior guideline‑recommended topical or systemic therapy failure, intolerance, or contraindication will be considered not medically necessary and may be denied without the required clinical context and supporting documentation.

Caution regarding specific devices: professional guidance and AAD reviews list multiple wavelengths and devices studied for acne (eg, 585–595 nm PDL, Nd:YAG, diode, KTP, IPL, red/blue light combinations), but current evidence does not substantiate sufficient efficacy for these specific devices to recommend routine use for acne—claims for benefit should be supported by high‑quality, indication‑specific evidence.

Rosacea scope: laser and IPL may be reasonable options for selected rosacea phenotypes (for example, persistent central facial erythema or telangiectasia) but use outside phenotype‑based recommendations or for indications lacking supportive evidence should be considered unproven. Device selection and expectation setting should reflect that some modalities show benefit in small studies while robust comparative evidence is limited.

The list of examples of unproven and not medically necessary light and laser therapies has been updated; notably, excimer was removed from the prior list of unproven/not medically necessary therapies in this revision.

Applicable Procedure and Diagnosis Codes

Fractional ablative laser fenestration billing unit

Billing Note: Fractional Ablative Laser Fenestration Unit

Prior Authorization, Documentation, and Operational Guidance

Billing Rule

Coding referenced for authorization

The following coding is referenced for prior authorization and claims adjudication. Inclusion of a code in this policy does not guarantee coverage; check member benefits and applicable laws.

CPT 17106 — Destruction of cutaneous vascular proliferative lesions; <10 sq cm
CPT 17107 — Destruction of cutaneous vascular proliferative lesions; 10–50 sq cm
CPT 17108 — Destruction of cutaneous vascular proliferative lesions; >50 sq cm
CPT 0479T — Fractional ablative laser fenestration of burn/traumatic scars; first 100 cm2 (or 1% BSA for infants/children)
CPT 0480T — Fractional ablative laser fenestration; each additional 100 cm2 (or 1% BSA)
CPT 17999 — Unlisted procedure, skin/mucous membrane/subcutaneous tissue (used for some laser hair removal and other unlisted laser procedures)

Background and Scope

Background: Vascular cutaneous lesions such as port‑wine stains and infantile hemangiomas are commonly treated with pulsed dye laser (PDL). PDL devices are flashlamp‑pumped systems emitting wavelengths targeted to cutaneous vasculature and frequently use epidermal cooling (eg, cryogen spray) to protect the epidermis and improve safety and tolerability. PDL is the most studied laser in cutaneous vascular lesions.

Definitions and Key Terms

Pulsed Dye Laser (PDL) — definition and context

DefinitionPulsed Dye Laser (PDL): a flashlamp‑pumped laser developed to treat cutaneous vascular lesions by emitting a specific wavelength of light targeted to blood vessels; cryogen spray cooling (CPDL) may be used to protect the epidermis.

Primary indicationsUsed for port‑wine stains (PWS) and cutaneous hemangiomas to lighten, reduce size, or cause regression of vascular lesions and to prevent or relieve complications.

Evidence contextPDL is the most studied laser type for infantile hemangiomas; comparative studies often assess variations of PDL and report greater improvements versus observation in many series, though protocols vary.

Coding notePDL procedures for cutaneous vascular lesions are reported using CPT codes 17106–17108 based on treated surface area; warts should not be reported with these vascular lesion codes.

Fractional ablative laser fenestration — definition and purpose

Policy Revision History

Note

Operational change: CPT 96999 removed from Applicable Codes

CPT code 96999 was removed from the policy's Applicable Codes list in the recent revisions; providers should not rely on this unlisted code for authorization or claims.

Policy Summary

PayerUnitedHealthcare

PolicyLight and Laser Therapy

Policy CodePolicy CS069.T

Change TypeRevisions to examples of unproven therapiesCPT code removalcontent edits

Effective DateFebruary 1, 2026

Next Review DateN/A

SourceLink

On This Page

Evidence from meta-analyses suggests laser combined with topical antifungal agents is superior to topical agents alone for clinical and mycological outcomes in some studies, but overall evidence quality ranges low to moderate and heterogeneity is high; consider as adjunctive therapy after or alongside standard antifungal regimens with clear documentation.

document prior or concurrent topical/systemic therapy; severity assessment (OSI/SCIO)

Multiple systematic reviews/meta-analyses report improved outcomes with combination therapy but call for larger RCTs.

Onychomycosis — laser monotherapy: Randomized and nonrandomized trials report variable and often low mycological cure rates for laser monotherapy; evidence insufficient to support laser as standalone primary therapy for OM.prefer adjunctive use; if requested, require justification and prior-treatment failure documentation

Cochrane and other reviews note uncertainty and low-quality evidence.

Rosacea and rhinophyma: Current evidence is insufficient to broadly recommend light and laser therapy for rosacea and rhinophyma due to small, heterogeneous studies; some modalities (IPL, PDL, KTP, CO2, Er:YAG, LPAL) show efficacy in small studies or comparative trials but require more robust data for broad coverage; consider for select patients with documentation of prior standard therapy failure or as cosmetic/elective—coverage depends on clinical context and payer policy.document prior medical therapy failure/intolerance; severity and objective photographic documentation recommended

Systematic reviews and comparative studies report improvements but limited by study quality and sample size.

Specialty guidance emphasizes limited/low quality evidence and recommends devices as alternatives or adjuncts rather than universally first-line.

Prior Authorization

Prior authorization for laser epilation in pilonidal sinus disease

Laser epilation for pilonidal sinus disease (PSD) may be considered medically necessary as an adjunct to surgical management to control hair regrowth when clinically indicated. Prior authorization may be requested to confirm indication and that recommended conservative/surgical care and perioperative hair removal counseling were provided.

Standard care education on hair removal documented (e.g., supplies provided, instructions to continue hair removal until age ~30)
Report number of laser sessions planned and device/wavelength (e.g., diode 810 nm for Fitzpatrick I–IV; Nd:YAG 1064 nm for Fitzpatrick V–VI)
Document prior surgical procedures (e.g., trephination, incision and drainage) and recurrence history

Prior Authorization

Prior authorization: require prior standard therapy and rationale

Requests for device-based therapies (light/laser) should document prior standard therapies tried and the clinical rationale for escalation to device therapy. Prior authorization may be required to confirm that conservative or guideline-recommended medical therapy was attempted and/or not tolerated.

For acne: document trials of topical (e.g., benzoyl peroxide, retinoids, topical antibiotics) and systemic therapies (e.g., oral antibiotics, isotretinoin) and reasons for failure or intolerance before PDT or laser for moderate–severe acne
For rosacea: document topical/systemic therapy trials and phenotype-directed rationale before device therapy
For onychomycosis: document prior topical and/or systemic antifungal therapy when device therapy is requested; note that device therapy is often adjuvant

Prior Authorization

Prior authorization recommended for device-based rosacea therapies

Device-based therapies for rosacea (e.g., IPL, PDL, KTP, Nd:YAG, CO2, Er:YAG) have variable evidence quality. Prior authorization is recommended to verify documented prior medical therapy, treatment phenotype, and expected benefit.

Document rosacea phenotype (erythematotelangiectatic, papulopustular, phymatous, granulomatous)
Provide prior medication history and responses (topical alpha-agonists, metronidazole, azelaic acid, oral agents)
Indicate device type, treatment endpoints, and plan for concurrent/adjunctive medical therapy

Note

Check benefit requirements and use of utilization tools

Before applying policy criteria, check the member's benefit plan (federal/state/contractual) and any utilization management tools (e.g., InterQual). Policy language does not override applicable federal, state, or contractual requirements.

Verify benefit coverage and any state mandates
Confirm use of third-party utilization criteria (e.g., InterQual) if applicable
In case of conflict, federal/state/contractual requirements govern

Documentation Required

Documentation may be required

Medical records and supporting documentation may be required to determine whether the member meets clinical criteria for coverage. Submission of records does not guarantee approval; absence of required documentation may result in denial.

Include clinic notes, prior treatment records, operative reports, and relevant imaging/photos
Provide objective assessment scores when applicable (e.g., VSS/mVSS, POSAS, IGA, OSI, SCIO)
Missing documentation demonstrating clinical criteria or prior therapy may lead to denial

Denial Risk

Evidence limitations may trigger denial

Limited or low-quality evidence for many light and laser indications may lead to denial when clinical benefit is unproven. When evidence is insufficient or heterogeneous, prior authorization reviewers may deny requests lacking robust supporting data or appropriate prior therapy.

Treatments listed as unproven/not medically necessary include acne vulgaris, onychomycosis, rhinophyma, and rosacea in many contexts — supply indication-specific evidence when requesting coverage
Low/very low quality evidence supporting fractional laser for functional impairment/keloid may affect approval decisions
Requests for treatments without comparative efficacy or long-term outcomes should include rationale and documented failure/intolerance of guideline therapies

Documentation Required

Procedure and follow-up documentation

For device-based procedural planning and follow-up, document treatment parameters, session counts, and patient-specific factors that affect safety and efficacy.

Record device type, wavelength, settings (fluence, pulse duration), and target area size per session
Report number and dates of planned and completed sessions and interval between treatments (e.g., every 4–6 weeks)
Document Fitzpatrick skin type, hair characteristics (for epilation), and any concurrent procedures (e.g., excision, trephination)

Documentation Required